Plenary Session 9 Live Now! Don’t miss this important session focused on Non-Steroidal MRAs in Cardio-Renal-Metabolic Care at e-Space CRM 2025. Learn from global experts on how these treatments are shaping clinical practice in heart kidney and liver management. Join us for a

Καλό μήνα με ένα τεράστιο χαμόγελο! 😄🏆

INTERESTING SURVEY FOR HEALTH CARE PROFESSIONALS ABOUT THE GUIDELINES. Follow the link: https://t.co/p8fqu5PvlH

Στοργή και χάδι ... πόσο ανάγκη το έχει κάθε ψυχή...❤️

#Finerenone significantly ⬇️ the risk of all-cause and CV #mortality vs. placebo in patients with #T2D across a broad spectrum of #CKD stages 🫀 More at #ehjcvp https://t.co/V2uIFuAFJl #CardioTwitter #EHJPharmacotherapy #Cardiology #kidney @AgewallStefan @Filippatos @JJheart_doc

A study from @MassEyeAndEar shows that approximately one quarter of Americans who had COVID-19 never fully recovered their sense of taste or smell, which has impacted their quality of life (via @NBC10Boston)

Happy Father’s Day to all those fortunate enough to take on the role of being a dad or father-figure. To Malia and Sasha, being your dad will always be the greatest gift of my life.

13 cases in 6.30h (9 cryoablation, 2 PMs and 2 ILRs). Team work is the secret! @ipetemil @athsaplaouras @SteliosDragasis @MEfraimidis plus I. Patsiotis #onassiscardiacsurgerycenter

The case for UACR for cardiologists: BP/lipids are modifiable CV risk factors is well known. CKD is a CV risk factor, but is it modifiable? https://t.co/qpxUNeTzHk @P_Rossing @Filippatos @KatherineTuttl8 @mvaduganathan @ChristophWanne4 @sameerbansilal @gbakris

Absolutely agree. With great faculty and friendly environment…as always @GMCRosano @MarcoMetra @MariannaAdamo1 @cardioceptor @m_piepoli @GianluSava @ShelleyZieroth @JavedButler1 @JBauersachsMD @HillLoreena @EkateriniL @HanCardiomd @ARakisheva @Filippatos

Here is a new metric: number of pictures taken during a presentation Congratulations all for this inspiring, lively, highly participated HFA course on Advanced HF! ⁦@HFA_President⁩ ⁦@WilfriedMullens⁩ ⁦@MariannaAdamo1⁩ ⁦@MRMehraMD⁩ ⁦@escardio⁩

Finerenone reduces mortality in chronic kidney disease and type 2 diabetes while on treatment: a FIDELITY analysis https://t.co/PdEkovbz9U @Stenodiabetes @Filippatos @AgarwalRajivMD @BakrisGeorge

Illusion of knowledge is more dangerous than ignorance: It's Okay to say "I don't know" and admit that you don't know it. It's shameful to pretend that you know everything.

You would like to learn the best novelties on rapid implementation of HF therapies? Come tomorrow at 8:30 am in Main Event II near the entrance at the right side. You will be the first to hear about STRONG-HF @univ_paris_cite @Inserm @HopLariboisiere

Further reading @ https://t.co/VmEvpSSQ7r (5/5) @WilsonTangMD @EvelyneMeekers @petra_nijst @JeroenDauw @kevin_damman @AlexMebazaa @MarcoMetra @Filippatos @robmentz @jozinetm @Uhasselt @futurehealthzol @KCETrials @HanCardiomd

@AndreasGevaert @hvanspall @mvaduganathan @JJheart_doc @SABOURETCardio @HFpEF @Filippatos #SGLT2i established class I for - #HFrEF - #HFmrEF - #HFpEF - #TDM - #CKD - #AHF Enjoy the last metanalysis on the @TheLancet Leave non #HF specialist in their personal opinion (level of evidence C) @US_FDA & @EMA_News already approved all these indications (#AHF ongoing) @gcfmd

Δεν υπάρχει δεν μπορώ στη ζωή!!

UACR is a HF marker. Consistent benefits across eGFR & UACR categories with finerenone in HF-related outcomes in pts with CKD and T2D. Results from FIDELITY (Combined FIDELIO-DKD and FIGARO-DKD Analysis) @JACCJournals #JACCHF https://t.co/XiAMtXYXw9 @Filippatos @BakrisGeorge

You are free to choose, but you are not free from the consequence of your choice.

Missed out on our session on comparing the recent European 🇪🇺 & US 🇺🇸 guidelines on #heartfailure? Access video-on-demand: https://t.co/Bjh0Nj7fjK #CardioEd #MedEd #eSPACEHF22